Page last updated: 2024-11-07

acth (4-10)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ACTH (4-10): part of ACTH molecule containing amino acids 4-10 of total 39 amino acid chain; heptapeptide common to MSH & ACTH; RN given refers to glycine cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID123787
CHEMBL ID2028951
MeSH IDM0057672

Synonyms (23)

Synonym
4037-01-8
acth 4-10
acth (4-10)
acth - msh (4-10)
msh-acth (4-10)
n-(n-(n(2)-(n-(n-(n-l-methionyl-l-alpha-glutamyl)-l-histidyl)-l-phenylalanyl)-l-arginyl)-l-tryptophyl)glycine
(4s)-4-[[(2s)-2-amino-4-methylsulfanylbutanoyl]amino]-5-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-(carboxymethylamino)-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol-
porcine acth (4-10)
corticotropin (4-10)
human acth (4-10)
CHEMBL2028951
unii-j48au3i790
j48au3i790 ,
glycine, l-methionyl-l-.alpha.-glutamyl-l-histidyl-l-phenylalanyl-l-arginyl-l-tryptophyl-
(5s,8s,11s,14s,17s)-14-((1h-imidazol-4-yl)methyl)-5-((1h-indol-3-yl)methyl)-17-((s)-2-amino-4-(methylthio)butanamido)-11-benzyl-8-(3-guanidinopropyl)-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazaicosane-1,20-dioic acid
h-met-glu-his-phe-arg-trp-gly-oh
CS-0044415
HY-P1478
Q27281179
MS-31803
4-10-corticotropin
DTXSID001031210
PD100148

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Both methods yielded the same dose-response profile."( Trophic influences of alpha-MSH and ACTH4-10 on neuronal outgrowth in vitro.
Bär, PR; Gispen, WH; Sodaar, P; Van der Neut, R,
)
0.13
" In post-test locomotor activity determination, an apparent dose-response existed for MSH/ACTH 4-10 with the two highest doses (190 and 285 micrograms/kg) resulting in significantly increased locomotor activity."( The effect of MSH/ACTH 4-10 on delayed response performance and post-test locomotor activity in rats.
Miller, LH; Turnbull, BA,
)
0.13
" Furthermore, dose-response characteristics of these influences should be examined."( Dose-dependent influences on electrophysiological signs of attention in humans after neuropeptide ACTH 4-10.
Born, J; Bräuninger, W; Fehm, HL; Fehm-Wolfsdorf, G; Pauschinger, P; Voigt, KH, 1987
)
0.27
" This dosage increases MAP and MC amplitudes and reduces fatigue."( Neurotropic action of MSH/ACTH 4-10 on neuromuscular function in hypophysectomized rats.
Gonzalez, ER; Strand, FL, 1981
)
0.26
"5 mg and 5 mg, Org O163 in a dosage of 30 mg."( [Effects of synthetic neuropeptides in psycho-organic brain syndrome. Results with ACTH4-10 and ACTH4-9-analog (author's transl)].
Fischer, PA; Jacobi, P; Schneider, E; van Riezen, H; Voerman, JW, 1981
)
0.26
" The potential impact of corticosteroid dosage levels (high versus low) and treatment regimens (daily versus alternate day) on attention and memory is discussed."( The influence of corticosteroids and theophylline on cerebral function. A review.
Dirks, JF; Schraa, JC, 1982
)
0.26
" The heterozygous parents were found to have high normal or mildly elevated body weight, suggesting a dosage effect of the POMC gene product on weight regulation."( Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10.
Biebermann, H; Grüters, A; Krude, H; Mullis, PE; Schnabel, D; Tansek, MZ; Theunissen, P, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID34308In vitro potency of compound to stimulate adenylate cyclase activity in melanoma cells relative to alpha-MSH; Not determined1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Comparative biological activities of highly potent active-site analogues of alpha-melanotropin.
AID102012In vitro potency of compound to stimulate melanosome dispersion in lizard skin relative to alpha-MSH1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Comparative biological activities of highly potent active-site analogues of alpha-melanotropin.
AID71943In vitro potency of compound to stimulate melanosome dispersion in frog (Rana pipiens) skin relative to alpha-MSH1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Comparative biological activities of highly potent active-site analogues of alpha-melanotropin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (153)

TimeframeStudies, This Drug (%)All Drugs %
pre-199092 (60.13)18.7374
1990's38 (24.84)18.2507
2000's20 (13.07)29.6817
2010's3 (1.96)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.31 (24.57)
Research Supply Index5.31 (2.92)
Research Growth Index3.99 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (8.02%)5.53%
Reviews5 (2.67%)6.00%
Case Studies1 (0.53%)4.05%
Observational0 (0.00%)0.25%
Other166 (88.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]